Kinga H. S.
- Country
- Poland
- Department
- Oncology
Research Overview
- Evaluation of Ribociclib Combined with Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Phase III Randomized Trial
- Phase 3 Randomized Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in Triple-Negative Breast Cancer Post-Neoadjuvant Therapy
- Phase 3 Study of Sacituzumab Tirumotecan With/Without Pembrolizumab in PD-L1 CPS <10 Triple-Negative Breast Cancer
Data & Insights
Has run more than one trial at 116 of 299 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in treating hormone receptor-positive (HR+), HER2-negative early breast cancer, with particular focus on developing innovative therapeutic approaches using endocrine therapy combinations.
- Early-stage breast cancer management
- Hormone receptor-positive disease treatment
- Endocrine therapy optimization
Key interests include evaluating novel therapeutic combinations to improve patient outcomes in early-stage breast cancer settings.
Prostate Cancer Treatment
The investigator focuses on advanced treatments for metastatic castration-resistant prostate cancer (mCRPC), exploring novel therapeutic approaches and combinations.
- Advanced prostate cancer management
- Novel hormonal therapy applications
- Treatment-resistant disease approaches
Areas of investigation include innovative combination therapies for patients with various stages of treatment progression in mCRPC.
Therapeutic Innovation
This investigator demonstrates expertise in targeted combination therapy development, particularly focusing on hormone-dependent cancers and resistance mechanisms.
- Drug resistance management
- Combination therapy optimization
- Treatment sequencing strategies
Research emphasis includes evaluating novel therapeutic agents in combination with established treatments.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.